Jonna et al. [54] reported that, among 21,858 patients with a variety of tumor types, although ultra-rare, NRG1 fusions were detected in malignancies including sarcoma, non-small cell lung cancer, gallbladder, pancreatic, renal, ovarian, breast, bladder, and colorectal cancers, with several fusion partners observed (Table 2) [23, 29, 54–60]. This evidence concerns the gene NRG1 and non-small cell lung carcinoma.